Inhibition of puerperal lactation with 2-mercaptopropionyl-glycine. 2000

C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
Obstetrics and Gynaecology Clinic, General Hospital of Ioannina, Greece.

OBJECTIVE Thiols (sulfydryl compounds) have a prolactin-lowering effect in animals. The purpose of our study was to evaluate the effects of orally administered N-2-mercaptopropionyl-glycine (tiopronin) on suppression of lactation and plasma prolactin (PRL) levels in a group of women in the puerperium. METHODS One hundred women aged 17-37 years were studied. We divided our population in four groups (25 patients in each group). In group I, no medication was administered but only conservative measures were taken (restriction of fluid intake, ice-bags applied on the breasts, tight breast binders). Subjects in group II received tiopronin (200 mg/day) for 14 days. In group III, tiopronin (500 mg/day) was administered for 14 days. Subjects in group IV, took bromocriptine (5 mg/day) for 14 days. Assessment of suppression of lactation was performed clinically and laboratory determinations were obtained before and after 1, 2, 3, 4, and 14 days of treatment. Furthermore, in seven healthy women plasma PRL responses to thyrotropin-releasing hormone (TRH) before and after one week of tiopronin therapy (500 mg/day) were studied. RESULTS Statistically significant higher percentages of success of lactation suppression were obtained with tiopronin (84% and 88%) and bromocriptine (96%) compared to conservative treatment (60%). In the four groups a significant decrease of PRL was observed. However, in women who received tiopronin and bromocriptine, the levels of PRL after 14 days of therapy were lower compared to the conservative treatment group. Moreover, in the tiopronin groups and the bromocriptine group, lactation was stopped earlier. In the first group (conservative measures) the lactation was suppressed after 13.3+/-5.4 days of treatment. In the groups who received tiopronin (200 mg/day and 500 mg/ day) lactation was suppressed after 4.4+/-1.7 and 4.3+/-1.6 days of treatment. In the bromocriptine group the lactation was stopped after 1.2+/-0.4 days. Bromocriptine treatment was associated with more frequent side effects than the tiopronin. CONCLUSIONS Administration of tiopronin in low to moderate doses is effective in suppression of puerperal lactation.

UI MeSH Term Description Entries
D007774 Lactation The processes of milk secretion by the maternal MAMMARY GLANDS after PARTURITION. The proliferation of the mammary glandular tissue, milk synthesis, and milk expulsion or let down are regulated by the interactions of several hormones including ESTRADIOL; PROGESTERONE; PROLACTIN; and OXYTOCIN. Lactation, Prolonged,Milk Secretion,Lactations, Prolonged,Milk Secretions,Prolonged Lactation,Prolonged Lactations
D008625 Tiopronin Sulfhydryl acylated derivative of GLYCINE. Mercaptopropionylglycine,Thiopronine,2-Mercaptopropionylglycine,2-Thiol-propionamido-acetic Acid,2-Thiolpropionamidoacetic Acid,Acadione,Captimer,Meprin,Thiola,Tiopronine,alpha-Mercaptopropionylglycine,2 Mercaptopropionylglycine,2 Thiol propionamido acetic Acid,2 Thiolpropionamidoacetic Acid,Acid, 2-Thiol-propionamido-acetic,Acid, 2-Thiolpropionamidoacetic,alpha Mercaptopropionylglycine
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D049590 Postpartum Period In females, the period that is shortly after giving birth (PARTURITION). Puerperium,Postpartum,Postpartum Women,Period, Postpartum,Women, Postpartum

Related Publications

C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
September 1972, Schweizerische medizinische Wochenschrift,
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
January 1995, Zeitschrift fur Geburtshilfe und Neonatologie,
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
July 1979, Archives of gynecology,
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
January 1981, International archives of allergy and applied immunology,
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
January 1980, Archivio di ostetricia e ginecologia,
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
January 1978, Acta endocrinologica. Supplementum,
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
January 1977, Rivista italiana di ginecologia,
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
June 2009, Journal of molecular and cellular cardiology,
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
November 1982, British medical journal (Clinical research ed.),
C Akrivis, and P Vezyraki, and D N Kiortsis, and A Fotopoulos, and A Evangelou
October 1982, British medical journal (Clinical research ed.),
Copied contents to your clipboard!